Zydus injectable facility in Vadodara gets U.S. FDA inspection report with VAI status

The U.S. Food and Drug Administration has issued an constitution inspection study (EIR) with a voluntary enactment indicated (VAI) classification to an injectable installation of Zydus Lifesciences successful Vadodara.

The institution received the EIR for a GMP follow-up inspection the U.S. FDA conducted astatine the installation successful Jarod, Vadodara, from August 25 to September 5, 2025 classifying the portion arsenic VAI. The inspection followed a informing missive issued connected August 29, 2024 by the U.S. FDA, the institution said.